Results 141 to 150 of about 33,833,464 (200)

Erratum: Deciphering the performance of polo-like kinase 1 in triple-negative breast cancer progression according to the centromere protein U-phosphorylation pathway. [PDF]

Am J Cancer Res
Zhao S, Geng Y, Cao L, Yang Q, Pan T, Zhou D, Liu J, Shi Z, Zhang J.   +8 more
europepmc   +1 more source

Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis. [PDF]

Front Oncol, 2023
Wei X, Song M, Huang C, Yu Q, Jiang G, Jin G, Jia X, Shi Z.   +7 more
europepmc   +1 more source

Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer. [PDF]

Oncogene
Jayachandran P, Elliott A, Soni S, Battaglin F, Mittal P, Algaze S, Lo JH, Yang Y, Ashouri K, Roussos Torres ET, Zhang W, Millstein J, Zhang L, Yu J, Lenz HJ.   +14 more
europepmc   +1 more source

The mitotic regulator polo-like kinase 1 as a potential therapeutic target for c-Myc-overexpressing canine osteosarcomas. [PDF]

Vet Comp Oncol, 2022
Gola C, Licenziato L, Accornero P, Iussich S, Morello E, Buracco P, Modesto P, Aresu L, De Maria R.   +8 more
europepmc   +1 more source

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinoma. [PDF]

J Cancer Res Clin Oncol, 2023
Feng Y, Li T, Lin Z, Li Y, Han X, Pei X, Fu Z, Wu Q, Shao D, Li C.   +9 more
europepmc   +1 more source

Overexpression of oncogenic polo-like kinase 1 disrupts the invasiveness, cell cycle, and apoptosis in synovial sarcoma. [PDF]

J Transl Med
Zhang J, Li Z, Xie MY, Wang N, Liu H, Li F, Pang LJ, Qi Y.   +7 more
europepmc   +1 more source

Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. [PDF]

Cancer Lett
Shah PA, Mazumdar T, Ghosh S, Yapindi L, Powell RT, Park YS, Shen L, Fernandez AM, Stephan CC, Wang J, Sikora AG, Kazi J, Frederick MJ, Johnson FM.   +13 more
europepmc   +1 more source

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. [PDF]

Mol Cancer Ther
Nouri M, Varkaris A, Ridinger M, Dalrymple SL, Dennehy CM, Isaacs JT, Einstein DJ, Brennen WN, Balk SP.   +8 more
europepmc   +1 more source

Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib. [PDF]

Int J Mol Sci
Fischer J, Erkner E, Radszuweit P, Hentrich T, Keppeler H, Korkmaz F, Schulze-Hentrich J, Fitzel R, Lengerke C, Schneidawind D, Schneidawind C.   +10 more
europepmc   +1 more source

Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer. [PDF]

Cancers (Basel)
Zhang G, Pannucci A, Ivanov AA, Switchenko J, Sun SY, Sica GL, Liu Z, Huang Y, Schmitz JC, Owonikoko TK.   +9 more
europepmc   +1 more source